Skip to main content

ENHERTU AstraZeneca Pty Ltd

Product name
ENHERTU
Accepted date
Nov-2024
Active ingredients
trastuzumab deruxtecan
Proposed indication
ENHERTU is for the treatment of adults with HER2-low or HER2-ultralow breast cancer that cannot be removed by surgery or has spread to other parts of the body. It is for patients who have already tried at least one hormone therapy for their metastatic cancer (HER2 is a cell surface protein that promotes cancer cell growth when activated).
Application type
C (new indication)
Publication date
Nov-2024

Help us improve the Therapeutic Goods Administration site